COMMUNIQUÉS West-GlobeNewswire
-
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
17/03/2026 -
Elicio Therapeutics Reports Inducement Grants
17/03/2026 -
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
17/03/2026 -
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
17/03/2026 -
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026 -
Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference
17/03/2026 -
Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™
17/03/2026 -
Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic
17/03/2026 -
CMR Surgical Advances Physical AI to Support the Future of Robotic Surgery with NVIDIA
17/03/2026 -
Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Address Evolving NHS Cyber Security and Compliance Challenges
17/03/2026 -
Transactions in connection with share buy-back program
17/03/2026 -
Tecan to create Data-Driven Labs with NVIDIA
17/03/2026 -
Aesthetics International Launches Medical-Grade Abdominoplasty Program to Help Address Chronic Back Pain
17/03/2026 -
Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
16/03/2026 -
Imprivata Introduces New Advanced Access Management and Passwordless Authentication Capabilities to Enhance Clinical Efficiency, Security, and Essential Eight Compliance
16/03/2026 -
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/03/2026 -
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
16/03/2026 -
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026 -
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
16/03/2026
Pages